Regeneron Pharmaceuticals, Inc.
Close on Nov 18, 2026Market cap $97.81BP/E 20.9Yield –
Regeneron Pharmaceuticals CEO Pay Ratio (X:1) [annual] by Year
Regeneron Pharmaceuticals CEO Pay Ratio (X:1) [annual]: 42.00 in FY2025, up 2.4% from a year earlier.
Where the FY2025 figure comes from
“Accordingly, the ratio of the 2025 annual total compensation of Dr. Schleifer to the median of the 2025 annual total compensation of our employees was approximately 42 to 1”
Source: Proxy Statement (DEF 14A) (regn-20260424.htm, filed 2026-04-24) ↗
Reported in DEF 14A Proxy Statements — CEO Pay Ratio Disclosure.
annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | CEO Pay Ratio (X:1) [annual] | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 42.00 | +2.4% | Proxy Statement (DEF 14A) (regn-20260424.htm, filed 2026-04-24) ↗ |
| FY2024 | Dec 31, 2024 | 41.00 | -16.3% | Proxy Statement (DEF 14A) (regn013211-def14a.htm, filed 2025-04-29) ↗ |
| FY2023 | Dec 31, 2023 | 49.00 | +14.0% | Proxy Statement (DEF 14A) (lregn2024_def14a.htm, filed 2024-04-25) ↗ |
| FY2022 | Dec 31, 2022 | 43.00 | 0.0% | Proxy Statement (DEF 14A) (lregn2023_def14a.htm, filed 2023-04-21) ↗ |
| FY2021 | Dec 31, 2021 | 43.00 | -95.4% | Proxy Statement (DEF 14A) (c102797_def14a.htm, filed 2022-04-21) ↗ |
| FY2020 | Dec 31, 2020 | 933.00 | +505.8% | Proxy Statement (DEF 14A) (c101011_def14a.htm, filed 2021-04-23) ↗ |
| FY2019 | Dec 31, 2019 | 154.00 | – | Proxy Statement (DEF 14A) (c95145_def14a.htm, filed 2020-04-24) ↗ |
Breakdown
What makes up CEO Pay Ratio (X:1) [annual]
Cite this data
StockData. (2026). Regeneron Pharmaceuticals CEO Pay Ratio (X:1) [annual], annual FY2019–FY2025 [Data set]. Compiled from Regeneron Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/regn/kpis/proxy-pay-ratio
See every metric in the Regeneron Pharmaceuticals KPI table. Data updated Nov 4, 2026.
See a number that looks wrong?